Gastrointestinal Adverse Effects

Cross-source consensus on Gastrointestinal Adverse Effects from 1 sources and 5 claims.

1 sources · 5 claims

Risks & contraindications

Gastrointestinal adverse effects are a primary focus because they are common with metformin and may cause discontinuation and lower quality of life. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
A symptom score of 4 or higher for any gastrointestinal outcome is considered a severe adverse effect. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
The trial assesses abdominal pain, reflux, nausea, diarrhoea, and loss of appetite using a questionnaire. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
Metformin users had a 7.7-fold higher risk of gastrointestinal adverse effects than placebo users in prior evidence. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
Because metformin adverse effects are dose-dependent, the higher-dose group is expected to experience more adverse effects. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial